CDC Vaccine Official Resigns Amid Policy Shifts

Highlights

• Dr. Lakshmi Panagiotakopoulos resigned from the CDC amid shifting COVID-19 vaccine policies.
• Her departure follows controversial changes in vaccine recommendations announced by HHS Secretary Robert F. Kennedy Jr.
• CDC’s removal of COVID vaccine guidance for pregnant women and healthy children has drawn expert criticism.
• FDA officials supported the move, emphasizing the need for stronger clinical data for low-risk populations.
• Moderna’s mNEXSPIKE vaccine was recently approved for certain at-risk groups.
• The CDC plans further updates to its vaccine guidance, with ACIP set to meet this month.

Leadership Departure During COVID Vaccine Uncertainty

The U.S. Centers for Disease Control and Prevention (CDC) is experiencing internal disruption as a senior vaccine expert steps down amid evolving COVID-19 vaccination guidelines. Dr. Lakshmi Panagiotakopoulos, a seasoned CDC official and co-leader of the Advisory Committee on Immunization Practices (ACIP) work group on COVID-19 vaccines, has resigned after nearly a decade of service.

According to Reuters, Panagiotakopoulos communicated her resignation in an email to colleagues, stating,“My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role.”

The resignation, which she described as a “personal decision,” comes at a time when the U.S. vaccine landscape is under increasing scrutiny. Panagiotakopoulos, an expert in pediatric infectious diseases, is the latest in a string of public health voices responding to recent federal shifts.

Federal Revisions to Vaccine Guidance

The policy environment around COVID-19 vaccination has recently seen significant changes. Last week, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced the removal of COVID-19 vaccines from the CDC’s recommended immunization schedule for pregnant women and “healthy” children. He cited a lack of“clinical data to support the repeat booster strategy in children.”

Today, the COVID vaccine for healthy children and healthy pregnant women has been removed from @CDCgov recommended immunization schedule. Bottom line: it’s common sense and it’s good science. We are now one step closer to realizing @POTUS’s promise to Make America Healthy Again. pic.twitter.com/Ytch2afCLP

— Secretary Kennedy (@SecKennedy) May 27, 2025

The decision prompted concerns over the process used to implement such guidance. Public Citizen Health Research Group Director Dr. Robert Steinbrook criticized the move, emphasizing that CDC’s immunization schedules should be formulated“through the well-established federal consultation process, not single-handedly by the HHS Secretary.”

FDA Aligns with HHS Position

Supporting Kennedy’s position, FDA Commissioner Dr. Marty Makary appeared alongside him in a video statement, echoing that“there’s no evidence that healthy kids need [a COVID booster] today.” He was joined in this stance by Dr. Vinay Prasad, head of the Center for Biologics Evaluation and Research.

Both Makary and Prasad further detailed their position in an article published in The New England Journal of Medicine, where they advocated for “robust, gold-standard data” as a prerequisite for approving new COVID-19 vaccines for low-risk populations.

Regulatory Approvals and Ongoing Updates

Despite the changing guidance, vaccine development and regulatory approvals continue. Moderna’s latest-generation COVID-19 vaccine, mNEXSPIKE, has received FDA approval for use in adults aged 65 and older, as well as for individuals aged 12 to 64 who have at least one underlying risk factor for severe COVID. Novavax’s COVID vaccine was previously approved with similar usage limitations.

The CDC has acknowledged recent updates on its website, noting that “COVID recommendations have recently been updated for some populations.” The agency also confirmed it will update the site to reflect the revised immunization schedule.

Meanwhile, the ACIP is scheduled to convene later this month to discuss further vaccine recommendations, a meeting that could bring additional clarity—or further contention—to the nation’s immunization framework.